We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The AI software will help more medical professionals to accurately scan patients and improve the detection of cardiovascular diseases, the company said. Read More
The test demonstrated 94 percent sensitivity in detecting clinically significant prostate cancer in a recent validation study, the company said. Read More
Abbott has received FDA’s approval of its new Proclaim Plus spinal cord stimulation (SCS) system that allows physicians to program the device to treat evolving pain. Read More